MicroRNA as a Prognostic and Diagnostic Marker in T-Cell Acute Lymphoblastic Leukemia.
T-ALL
T-ALL markers
diagnostic marker
microRNA
predictive marker
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
13
04
2021
revised:
12
05
2021
accepted:
16
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
16
6
2021
Statut:
epublish
Résumé
T cell acute lymphoblastic leukemia (T-ALL) is a biologically and genetically heterogeneous disease with a poor prognosis overall and several subtypes. The neoplastic transformation takes place through the accumulation of numerous genetic and epigenetic abnormalities. There are only a few prognostic factors in comparison to B cell precursor acute lymphoblastic leukemia, which is characterized by a lower variability and more homogeneous course. The microarray and next-generation sequencing (NGS) technologies exploring the coding and non-coding part of the genome allow us to reveal the complexity of the genomic and transcriptomic background of T-ALL. miRNAs are a class of non-coding RNAs that are involved in the regulation of cellular functions: cell proliferations, apoptosis, migrations, and many other processes. No miRNA has become a significant prognostic and diagnostic factor in T-ALL to date; therefore, this topic of investigation is extremely important, and T-ALL is the subject of intensive research among scientists. The altered expression of many genes in T-ALL might also be caused by wide miRNA dysregulation. The following review focuses on summarizing and characterizing the microRNAs of pediatric patients with T-ALL diagnosis and their potential future use as predictive factors.
Identifiants
pubmed: 34070107
pii: ijms22105317
doi: 10.3390/ijms22105317
pmc: PMC8158355
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Blood Adv. 2017 May 04;1(12):733-747
pubmed: 29296717
PLoS One. 2014 Jan 13;9(1):e85201
pubmed: 24454819
Database (Oxford). 2020 Jan 1;2020:
pubmed: 32128558
Nat Rev Cancer. 2016 Jul 25;16(8):494-507
pubmed: 27451956
Tumour Biol. 2016 Jun;37(6):7861-72
pubmed: 26700663
J Exp Med. 2011 Apr 11;208(4):663-75
pubmed: 21464222
J Cell Mol Med. 2016 Oct;20(10):1898-907
pubmed: 27241533
Int J Mol Sci. 2019 Jun 20;20(12):
pubmed: 31226848
Brief Bioinform. 2019 Sep 27;20(5):1836-1852
pubmed: 29982332
Leuk Res. 2013 Sep;37(9):1027-34
pubmed: 23827350
J Cell Biochem. 2019 Apr;120(4):5936-5948
pubmed: 30362152
Cancer Cell. 2020 Feb 10;37(2):200-215.e5
pubmed: 32049046
Leuk Res. 2012 Jul;36(7):905-11
pubmed: 22424712
Cancer Res. 2009 May 15;69(10):4443-53
pubmed: 19435910
Mol Cancer. 2018 Jan 24;17(1):12
pubmed: 29368647
J Exp Med. 2013 Jul 29;210(8):1545-57
pubmed: 23857984
Oncol Lett. 2019 Feb;17(2):1791-1797
pubmed: 30675239
Blood Rev. 2018 Nov;32(6):457-472
pubmed: 29703513
Leuk Res. 2012 Mar;36(3):293-8
pubmed: 22099053
Leukemia. 2012 Apr;26(4):769-77
pubmed: 21979877
J Clin Oncol. 2017 Aug 10;35(23):2683-2691
pubmed: 28605290
Exp Hematol Oncol. 2013 Apr 08;2(1):10
pubmed: 23566596
Curr Hematol Malig Rep. 2018 Aug;13(4):265-274
pubmed: 29948644
Hum Pathol. 2013 Jun;44(6):1011-6
pubmed: 23260326
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241379
Adv Biol Regul. 2019 Dec;74:100650
pubmed: 31548132
Sci Rep. 2017 Aug 11;7(1):7901
pubmed: 28801656
Cancer Med. 2019 May;8(5):2553-2560
pubmed: 30848099
J Clin Oncol. 2011 Feb 10;29(5):551-65
pubmed: 21220611
Blood. 2015 Aug 20;126(8):993-1004
pubmed: 25979949
J Exp Clin Cancer Res. 2011 Dec 01;30:110
pubmed: 22133358
Cancer Manag Res. 2019 May 02;11:3933-3943
pubmed: 31118806
Leukemia. 2015 Apr;29(4):798-806
pubmed: 25231743
Lancet Oncol. 2009 Feb;10(2):147-56
pubmed: 19147408
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):436-441
pubmed: 32319375
Haematologica. 2010 Oct;95(10):1675-82
pubmed: 20494936
Mol Ther Nucleic Acids. 2018 Sep 7;12:184-194
pubmed: 30195757
Neoplasia. 2019 Mar;21(3):294-310
pubmed: 30763910
Leukemia. 2009 Feb;23(2):313-22
pubmed: 18923441
Haematologica. 2015 Oct;100(10):1301-10
pubmed: 26206799
J Pediatr. 2012 Jan;160(1):10-8
pubmed: 21920540
Blood. 2010 Nov 4;116(18):3622-6
pubmed: 20656931
Crit Rev Oncol Hematol. 2018 Jun;126:100-111
pubmed: 29759551
Br J Cancer. 2013 Oct 15;109(8):2189-98
pubmed: 24030073
Onco Targets Ther. 2019 Dec 16;12:11069-11082
pubmed: 31908476
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Biomed Pharmacother. 2018 Oct;106:1668-1677
pubmed: 30170355
Jpn J Clin Oncol. 2020 Jun 10;50(6):671-678
pubmed: 32129446
Sci Rep. 2016 Aug 23;6:31894
pubmed: 27550837
Cell Death Differ. 2010 Feb;17(2):215-20
pubmed: 19498445
Blood. 2016 Apr 14;127(15):1863-9
pubmed: 26747249
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):580-588
pubmed: 27913532
Mediterr J Hematol Infect Dis. 2014 Nov 01;6(1):e2014073
pubmed: 25408859
Hematology. 2020 Dec;25(1):405-413
pubmed: 33191875
Leuk Res. 2011 Feb;35(2):208-13
pubmed: 20570349
Pathol Oncol Res. 2015 Jul;21(3):597-604
pubmed: 25388103
Cancers (Basel). 2019 Jul 11;11(7):
pubmed: 31336701
Oncol Rep. 2016 Nov;36(5):2511-2516
pubmed: 27666896
Curr Probl Pediatr Adolesc Health Care. 2016 Jul;46(7):229-241
pubmed: 27283082
Hum Mol Genet. 2011 Dec 15;20(24):4903-15
pubmed: 21926415
Chem Biol Interact. 2020 Feb 1;317:108963
pubmed: 31978391
J Clin Invest. 2008 Nov;118(11):3762-74
pubmed: 18830414
Cancer Sci. 2014 Apr;105(4):463-72
pubmed: 24720529
Leuk Res. 2013 Jun;37(6):647-56
pubmed: 23522449
Leukemia. 2017 Nov;31(11):2355-2364
pubmed: 28280276